• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xilio Therapeutics, Inc. - Common Stock (NQ:XLO)

8.570 +0.220 (+2.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xilio Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
April 17, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
April 16, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
March 23, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Stock Jumps 8% On Cancer Drug Data; Gilead Boost Extends Cash Runway Into 2027 — Retail Says Stock Undervalued ↗
September 09, 2025
Via Stocktwits
News headline image
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
March 17, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
March 12, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference
March 02, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 02, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA
February 19, 2026
As of February 19, 2026, ImmunityBio, Inc. (NASDAQ: IBRX) stands at a pivotal crossroads between clinical ambition and commercial reality. Once a "story stock" fueled by the vision of its billionaire... 
Via Finterra
Topics Lawsuit
News headline image
Xilio Therapeutics Announces Pricing of Underwritten Offering
February 11, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates
January 08, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results
November 13, 2025
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
November 10, 2025
 
Via Benzinga
News headline image
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
November 07, 2025
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
November 07, 2025
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 03, 2025
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting
October 30, 2025
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
October 03, 2025
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2025
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
September 09, 2025
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Revenue Jumps 246 Percent in Q2 ↗
August 14, 2025
Via The Motley Fool
Topics Intellectual Property
News headline image
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results
August 14, 2025
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors
August 04, 2025
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2025
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2025
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
June 18, 2025
 
Via Benzinga
News headline image
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors
June 10, 2025
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Closing of $50.0 Million Public Offering
June 05, 2025
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 03, 2025
From Xilio Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap